Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience.

Tan, Eng-King; Albanese, Alberto; Chaudhuri, KRay; Lim, Shen-Yang; Oey, Nicodemus Edrick; Shan Chan, Christine Hui; Wu, Yun-Cheng; Jeon, Beomseok; Truong, Daniel; Poewe, Werner; Pal, Pramod Kumar; Tan, Louis; Opal, Puneet; Colosimo, Carlo; Jinnah, H A; Cardoso, Francisco
Parkinsonism & related disorders
2020Oct ; 83 ( 37 ) :.
ÀúÀÚ »ó¼¼Á¤º¸
Tan, Eng-King - National Neuroscience Institute, Singapore. Electronic address: gnrtek@sgh.com.sg.
Albanese, Alberto - IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy. Electronic address:
Chaudhuri, KRay - Kings College and Kings College Hospital, London, United Kingdom. Electronic
Lim, Shen-Yang - University of Malaya, Kuala Lumpur, Malaysia. Electronic address:
Oey, Nicodemus Edrick - National Neuroscience Institute, Singapore. Electronic address:
Shan Chan, Christine Hui - National Neuroscience Institute, Singapore. Electronic address:
Wu, Yun-Cheng - Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, China.
Jeon, Beomseok - Seoul National University Hospital, Seoul, South Korea. Electronic address:
Truong, Daniel - University of California, USA. Electronic address: dtruong@pmdi.org.
Poewe, Werner - Medical University of Innsbruck, Austria. Electronic address:
Pal, Pramod Kumar - National Neuroscience Institute of Mental Health and Neurosciences, Bangalore,
Tan, Louis - National Neuroscience Institute, Singapore. Electronic address:
Opal, Puneet - Northwestern University, USA. Electronic address: P-opal@northwestern.edu.
Colosimo, Carlo - Azienda Ospedaliera Santa Maria, Terni, Italy. Electronic address:
Jinnah, H A - Emory University School of Medicine, USA. Electronic address: hjinnah@emory.edu.
Cardoso, Francisco - Federal University of Minas Gerais, Belo Horizonte MG, Brazil. Electronic address:
ABSTRACT
keyword
COVID-19; Clinical research; Country-specific challenges; Parkinson's disease trials
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
Data interpretation in any PD clinical study has to be handled cautiously as neurological symptoms of COVID-19 may overlap with PD and related disorders and the long-term impact on PD is also unclear.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
10.1016/j.parkreldis.2020.10.009
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå